Eupraxia Pharmaceuticals Inc.

Stage 2 · Advancing · week 3

As of Oct 22, 2026, Eupraxia Pharmaceuticals is in Stage 2, the uptrend phase, now in week 3 (since Oct 5, 2026). It closed at $7.59, 16.6% below its 52-week high and above its 200-day average, which is rising.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. More about the company

$7.59

-1.81% today

$501M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is EPRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-04-05 → 2026-10-22

S? 42w

S2 13w

S2 42w

S3 12w

2024-04-052026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S2 3w → S3 2w → S2 13w → S3 2w → S2 42w → S3 12w → S4 9w → S1 6w → S2 3w current

Total tracked: 132 weeks across 10 stage runs.

EPRX among Biotechnology109th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…109	EPRXEupraxia Pharmaceuticals Inc.	Stage 2 · wk 3	81	−6.8%

vs 52W High

-16.6%

$5.33 lo$9.10 hi

16.6% below 52W high, deeper pullback

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 3

1w13w26w

Week 3, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

3.4%

200 DMA: $7.34 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.56x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-6.8%

+30.6%

+4.7%

YTD

+0.3%

+38.3%

Scan Membership

Breakout Watch

Latest: 2025-06-10

3 appearances in last 60 days. First seen: 2025-01-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 3 · Vol 0.56x

2026-10-21S2

Wk 3 · Vol 0.49x

2026-10-20S2

Wk 3 · Vol 1.38x

2026-10-19S2

Wk 3 · Vol 0.58x

2026-10-16S2

Wk 2 · Vol 0.87x

2026-10-15S2

Wk 2 · Vol 0.90x

2026-10-14S2

Wk 2 · Vol 0.42x

2026-10-13S2

Wk 2 · Vol 2.40x

2026-10-12S2

Wk 2 · Vol 0.39x

2026-10-09S2

Wk 1 · Vol 1.65x

2026-10-08S2

Wk 1 · Vol 0.99x

2026-10-07S2

Wk 1 · Vol 1.34x

Moving averages & range

50 DMA

$7.56

200 DMA

$7.34

52W High

$9.10

52W Low

$5.33

5D Low

$6.62

Resistance levels (recent highs)

20d High

$9.10

60d High

$9.10

120d High

$9.10

250d High

$9.10

Next resistance

+19.9%

to 20d High

ROE

-66.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 4.9

Eupraxia Pharmaceuticals: quick answers

What stage is Eupraxia Pharmaceuticals in?

As of Oct 22, 2026, Eupraxia Pharmaceuticals (EPRX) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 5, 2026 and is in week 3. What the four stages mean

Is Eupraxia Pharmaceuticals in an uptrend?

Yes. Eupraxia Pharmaceuticals is in a Stage 2 uptrend. It trades 3.4% above its 200-day average, which is rising.

How far is Eupraxia Pharmaceuticals from its 52-week high?

Eupraxia Pharmaceuticals closed at $7.59 on Oct 22, 2026, 16.6% below its 52-week high of $9.10. Its 52-week low is $5.33.

How has Eupraxia Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Eupraxia Pharmaceuticals is up 38.3% over the past year and up 0.3% so far in 2026.

Which sector and industry is Eupraxia Pharmaceuticals in?

Eupraxia Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.